Matches in SemOpenAlex for { <https://semopenalex.org/work/W2777261003> ?p ?o ?g. }
- W2777261003 endingPage "33.e1" @default.
- W2777261003 startingPage "23" @default.
- W2777261003 abstract "Key MessagesThe approach to refractory atopic dermatitis should include a step-wise approach to rule out other diagnoses, confirm adequate first-line therapy, and rule out exacerbating factors prior to implementing second-line therapies.•Immunodeficiencies and skin disorders can mimic atopic dermatitis•Topical skin care technique is paramount to prevent continual flares•It is difficult to identify triggers unless the patient is cleared first•Consider infection and allergens, but do not overlook scratching•Consider addressing behavioral factors using a multidisciplinary approachInstructionsCredit can now be obtained, free for a limited time, by reading the review article in this issue and completing all activity components. Please note the instructions listed below:•Review the target audience, learning objectives and all disclosures.•Complete the pre-test.•Read the article and reflect on all content as to how it may be applicable to your practice.•Complete the post-test/evaluation and claim credit earned. At this time, physicians will have earned up to 1.0 AMA PRA Category 1 CreditTM. Minimum passing score on the post-test is 70%.•Approximately 4-6 weeks later you will receive an online outcomes assessment regarding your application of this article to your practice. Once you have completed this assessment, you will be eligible to receive MOC Part II credit from the American Board of Allergy and Immunology.Overall PurposeParticipants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices.Learning ObjectivesAt the conclusion of this activity, participants should be able to:•Discuss diagnostic considerations in refractory atopic dermatitis•Describe an approach to the management of refractory atopic dermatitisRelease Date: January 1, 2018Expiration Date: December 31, 2019Target AudiencePhysicians involved in providing patient care in the field of allergy/asthma/immunologyAccreditationThe American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.DesignationThe American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Disclosure PolicyAs required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all CME planners, presenters, moderators, authors, reviewers, and other individuals in a position to control and/or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of ACAAI.Disclosure of Relevant Financial RelationshipsAll identified conflicts of interest have been resolved. Any unapproved/investigative uses of therapeutic agents/devices discussed are appropriately noted.Planning Committee•Jonathan A. Bernstein, MD (Annals CME Subcommittee): Consultant, Fees: Imedics; Consultant/Principal Investigator, Grants/Fees: Boehringer Ingelheim, GlaxoSmithKline; Consultant/Principal Investigator/Speaker, Grants/Fees: AstraZeneca, CSL Behring, Novartis/Genentech, Shire; Speaker, Fees: Baxalta•Guha Krishnaswamy, MD (Annals CME Subcommittee): Clinical Research, Grant: CSL Behring•Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief): Clinical Research, Grants: Sanofi, Stallergenes•Anna Nowak-Wegrzyn, MD (CME Series Editor, Deputy Editor): no relevant financial relationships to disclose.•John J. Oppenheimer, MD (Annals CME Subcommittee, Associate Editor): Consultant, Other financial gains: DBV Technologies, GlaxoSmithKline, Kaleo; Clinical Research, Grants: AstraZeneca, Boehringer Ingelheim, NovartisAuthor•Neema Izadi, MD, MS: has no relevant financial relationships to disclose.•Donald Y.M. Leung, MD, PhD: Advisory Board, Fees: Regeneron, Sanofi, Aimmune; Research, Grants: NIAMS, NIADIRecognition of Commercial Support: This activity has not received external commercial support.Copyright Statement: ©2015-2018 ACAAI. All rights reserved.CME Inquiries: Contact the American College of Allergy, Asthma & Immunology at [email protected]or 847-427-1200. The approach to refractory atopic dermatitis should include a step-wise approach to rule out other diagnoses, confirm adequate first-line therapy, and rule out exacerbating factors prior to implementing second-line therapies.•Immunodeficiencies and skin disorders can mimic atopic dermatitis•Topical skin care technique is paramount to prevent continual flares•It is difficult to identify triggers unless the patient is cleared first•Consider infection and allergens, but do not overlook scratching•Consider addressing behavioral factors using a multidisciplinary approach Credit can now be obtained, free for a limited time, by reading the review article in this issue and completing all activity components. Please note the instructions listed below:•Review the target audience, learning objectives and all disclosures.•Complete the pre-test.•Read the article and reflect on all content as to how it may be applicable to your practice.•Complete the post-test/evaluation and claim credit earned. At this time, physicians will have earned up to 1.0 AMA PRA Category 1 CreditTM. Minimum passing score on the post-test is 70%.•Approximately 4-6 weeks later you will receive an online outcomes assessment regarding your application of this article to your practice. Once you have completed this assessment, you will be eligible to receive MOC Part II credit from the American Board of Allergy and Immunology. Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices. At the conclusion of this activity, participants should be able to:•Discuss diagnostic considerations in refractory atopic dermatitis•Describe an approach to the management of refractory atopic dermatitis Release Date: January 1, 2018 Expiration Date: December 31, 2019 Physicians involved in providing patient care in the field of allergy/asthma/immunology The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all CME planners, presenters, moderators, authors, reviewers, and other individuals in a position to control and/or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of ACAAI. All identified conflicts of interest have been resolved. Any unapproved/investigative uses of therapeutic agents/devices discussed are appropriately noted. •Jonathan A. Bernstein, MD (Annals CME Subcommittee): Consultant, Fees: Imedics; Consultant/Principal Investigator, Grants/Fees: Boehringer Ingelheim, GlaxoSmithKline; Consultant/Principal Investigator/Speaker, Grants/Fees: AstraZeneca, CSL Behring, Novartis/Genentech, Shire; Speaker, Fees: Baxalta•Guha Krishnaswamy, MD (Annals CME Subcommittee): Clinical Research, Grant: CSL Behring•Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief): Clinical Research, Grants: Sanofi, Stallergenes•Anna Nowak-Wegrzyn, MD (CME Series Editor, Deputy Editor): no relevant financial relationships to disclose.•John J. Oppenheimer, MD (Annals CME Subcommittee, Associate Editor): Consultant, Other financial gains: DBV Technologies, GlaxoSmithKline, Kaleo; Clinical Research, Grants: AstraZeneca, Boehringer Ingelheim, Novartis •Neema Izadi, MD, MS: has no relevant financial relationships to disclose.•Donald Y.M. Leung, MD, PhD: Advisory Board, Fees: Regeneron, Sanofi, Aimmune; Research, Grants: NIAMS, NIADI Recognition of Commercial Support: This activity has not received external commercial support. Copyright Statement: ©2015-2018 ACAAI. All rights reserved. CME Inquiries: Contact the American College of Allergy, Asthma & Immunology at [email protected] or 847-427-1200." @default.
- W2777261003 created "2018-01-05" @default.
- W2777261003 creator A5023847975 @default.
- W2777261003 creator A5026388597 @default.
- W2777261003 date "2018-01-01" @default.
- W2777261003 modified "2023-10-17" @default.
- W2777261003 title "Clinical approach to the patient with refractory atopic dermatitis" @default.
- W2777261003 cites W1088236639 @default.
- W2777261003 cites W1850254945 @default.
- W2777261003 cites W189068515 @default.
- W2777261003 cites W1907388817 @default.
- W2777261003 cites W1922871350 @default.
- W2777261003 cites W1969256041 @default.
- W2777261003 cites W1969725546 @default.
- W2777261003 cites W1976568467 @default.
- W2777261003 cites W1980040943 @default.
- W2777261003 cites W1987936507 @default.
- W2777261003 cites W2003066780 @default.
- W2777261003 cites W2012434022 @default.
- W2777261003 cites W2030480507 @default.
- W2777261003 cites W2034153343 @default.
- W2777261003 cites W2040976653 @default.
- W2777261003 cites W2041157006 @default.
- W2777261003 cites W2062702626 @default.
- W2777261003 cites W2063478454 @default.
- W2777261003 cites W2069963552 @default.
- W2777261003 cites W2074314525 @default.
- W2777261003 cites W2088152362 @default.
- W2777261003 cites W2100509462 @default.
- W2777261003 cites W2103659544 @default.
- W2777261003 cites W2122070228 @default.
- W2777261003 cites W2124803404 @default.
- W2777261003 cites W2142327072 @default.
- W2777261003 cites W2150381738 @default.
- W2777261003 cites W2155331534 @default.
- W2777261003 cites W2155965505 @default.
- W2777261003 cites W2157425698 @default.
- W2777261003 cites W2171835211 @default.
- W2777261003 cites W2174132185 @default.
- W2777261003 cites W2219506845 @default.
- W2777261003 cites W2266186005 @default.
- W2777261003 cites W2289688129 @default.
- W2777261003 cites W2307159860 @default.
- W2777261003 cites W2346391788 @default.
- W2777261003 cites W2387317055 @default.
- W2777261003 cites W2400105324 @default.
- W2777261003 cites W2419578667 @default.
- W2777261003 cites W2466368575 @default.
- W2777261003 cites W2467414750 @default.
- W2777261003 cites W2471976905 @default.
- W2777261003 cites W2472155751 @default.
- W2777261003 cites W2474553364 @default.
- W2777261003 cites W2485314110 @default.
- W2777261003 cites W2508331598 @default.
- W2777261003 cites W2510992221 @default.
- W2777261003 cites W2547251709 @default.
- W2777261003 cites W2553111452 @default.
- W2777261003 cites W2555864064 @default.
- W2777261003 cites W2559039849 @default.
- W2777261003 cites W2566855475 @default.
- W2777261003 cites W2582755369 @default.
- W2777261003 cites W2588707751 @default.
- W2777261003 cites W2597544327 @default.
- W2777261003 cites W2604249065 @default.
- W2777261003 cites W2604389567 @default.
- W2777261003 cites W2604782609 @default.
- W2777261003 cites W2610814011 @default.
- W2777261003 cites W2611339841 @default.
- W2777261003 cites W2611397836 @default.
- W2777261003 cites W2620624134 @default.
- W2777261003 cites W2697539293 @default.
- W2777261003 cites W2767616012 @default.
- W2777261003 cites W59686197 @default.
- W2777261003 cites W177636634 @default.
- W2777261003 doi "https://doi.org/10.1016/j.anai.2017.09.061" @default.
- W2777261003 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8564861" @default.
- W2777261003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29273125" @default.
- W2777261003 hasPublicationYear "2018" @default.
- W2777261003 type Work @default.
- W2777261003 sameAs 2777261003 @default.
- W2777261003 citedByCount "13" @default.
- W2777261003 countsByYear W27772610032018 @default.
- W2777261003 countsByYear W27772610032019 @default.
- W2777261003 countsByYear W27772610032020 @default.
- W2777261003 countsByYear W27772610032021 @default.
- W2777261003 countsByYear W27772610032022 @default.
- W2777261003 crossrefType "journal-article" @default.
- W2777261003 hasAuthorship W2777261003A5023847975 @default.
- W2777261003 hasAuthorship W2777261003A5026388597 @default.
- W2777261003 hasBestOaLocation W27772610031 @default.
- W2777261003 hasConcept C121332964 @default.
- W2777261003 hasConcept C142424586 @default.
- W2777261003 hasConcept C16005928 @default.
- W2777261003 hasConcept C2778329239 @default.
- W2777261003 hasConcept C71924100 @default.
- W2777261003 hasConcept C87355193 @default.
- W2777261003 hasConceptScore W2777261003C121332964 @default.
- W2777261003 hasConceptScore W2777261003C142424586 @default.